Concealment and remineralisation of white spot lesions in enamel following topical application of TiON and 60% casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) and stannous fluoride in healthy adults

开始日期2025-11-11

申办/合作机构

University of Melbourne

NCT06048809

/ CompletedN/A

A Randomised, Controlled, Examiner Blind, Methodology Development Study to Evaluate the Effect of a Stannous Fluoride Toothpaste on the Oral Microbiome

The aim of this study is to evaluate the effect of a toothpaste containing stannous fluoride (SnF2) over time on the oral bacterial composition and activity and to explore its effect in comparison to a regular fluoride toothpaste.

开始日期2024-04-10

申办/合作机构

Haleon Plc

NCT05916521

/ CompletedN/A

A Three-Month Bleeding-Model Clinical Study

The objective of the study is to evaluate the gingivitis control benefit of an established stannous fluoride containing toothpaste relative to a negative control dentifrice.

开始日期2021-11-15

申办/合作机构

Procter & Gamble, Inc.

100 项与 Stannous protoporphyrin 相关的临床结果

登录后查看更多信息

100 项与 Stannous protoporphyrin 相关的转化医学

登录后查看更多信息

100 项与 Stannous protoporphyrin 相关的专利（医药）

登录后查看更多信息

项与 Stannous protoporphyrin 相关的文献（医药）

2015-07-01·Experimental physiology3区 · 医学

Renal protective effects of induction of haem oxygenase‐1 combined with increased adiponectin on the glomerular vascular endothelial growth factor–nitric oxide axis in obese rats

3区 · 医学

Article

作者: Liu, Xue ; Hou, Ningning ; Han, Fang ; Sun, Xiaodong ; Zang, Ping

New Findings:

What is the central question of this study?This study aimed to investigate whether induction of haem oxygenase‐1 (HO‐1) can protect the kidneys of obese rats by regulating the glomerular vascular endothelial growth factor–nitric oxide (VEGF–NO) axis by increasing the adiponectin concentrations.What is the main finding and its importance?Induction of HO‐1 reduces the degree of microalbuminuria and has renal protective effects by improving endothelial function and regulating the uncoupled glomerular VEGF–NO axis in diet‐induced obese rats. The mechanism may be related to increased activation of the HO‐1–adiponectin axis.The glomerular vascular endothelial growth factor–nitric oxide (VEGF–NO) axis plays a critical role in maintenance of normal kidney function in obesity. Induction of haem oxygenase‐1 (HO‐1) may result in a parallel increase in adiponectin secretion. The aim of this study was to investigate whether induction of HO‐1 could protect the kidneys of obese rats by regulating the glomerular VEGF–NO axis by increasing adiponectin levels. Rats received high‐fat diets and were injected with either cobalt protoporphyrin to induce HO‐1 or stannous protoporphyrin to inhibit HO‐1. Blood and urine samples were collected. Endothelial function was determined by measuring the endothelium‐dependent vasodilatation of the aorta. Renal tissues were collected for CD34 immunohistochemistry. The glomerular VEGF–NO axis and the AMP kinase–phosphoinositide 3‐kinase (PI3K)/Akt–endothelial nitric oxide synthase pathway were measured. Induction of HO‐1 by cobalt protoporphyrin decreased microalbuminuria, plasma free fatty acids, serum high‐sensitivity C‐reactive protein and malondialdehyde levels and increased serum adiponectin levels compared with the untreated obese rats. Severe impairment of endothelium‐dependent vasodilatation was observed in the obese rats, which was improved to some extent by HO‐1 induction. Induction of HO‐1 reduced glomerular CD34 expression and production of reactive oxygen species in obese rats. Obese rats showed increased glomerular VEGF expression and reduced NO levels. This uncoupling of the glomerular VEGF–NO axis was improved to some extent by induction of HO‐1, with enhancement of p‐AMP kinase, p‐Akt and phospho‐endothelial nitric oxide synthase in obese rats. These results indicate that induction of HO‐1 with cobalt protoporphyrin reduces the degree of microalbuminuria and has renal protective effects by improving endothelial dysfunction and regulating the glomerular VEGF–NO axis in diet‐induced obese rats by increasing adiponectin levels.

2015-01-01·Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Induction of Haemeoxygenase-1 Directly Improves Endothelial Function in Isolated Aortas from Obese Rats through the Ampk-Pi3k/Akt-Enos Pathway

Article

作者: Xu, Lili ; Han, Fang ; Guo, Ying ; Hou, Ningning ; Sun, Xiaodong ; Han, Fei

Background: Induction of haemeoxygenase-1 (HO-1) increases adiponectin secretion by remodeling adipose tissue in obesity. The objective of our study is to explore whether HO-1 induction directly improves endothelial function independent of adiponectin changes in obese rats. Methods: Rats were divided into control and obesity groups. Aortic endothelial function was determined by measuring endothelium-dependent vasodilatation (EDV). Vascular segments of the obese rats were incubated in an organ bath in the presence or absence of cobalt protoporphyrin (CoPP) or CoPP plus stannous protoporphyrin. Nitric oxide (NO) production, superoxide anion production and NF-κB p65 expression in the aorta were determined. The expression of AMP-activated kinase (AMPK), Akt and endothelial nitric oxide synthase (eNOS) in endothelial cells was determined by western blotting. The aortic rings from the obese rats were then incubated with CoPP in the presence of specific inhibitors of AMPK, phosphatidylinositol 3-kinase (PI3K) or eNOS. Results: Acetylcholine-induced EDV was significantly attenuated in the obese rats, compared with the NC group (p < 0.05). Pre-incubation of vessels from obese rats with CoPP significantly increased EDV (p < 0.05). However, this beneficial effect of CoPP was partly attenuated in vitro in the presence of inhibitors of AMPK, PI3K or eNOS. HO-1 induction with CoPP significantly increased the activation of the AMPK-PI3K/Akt-eNOS pathway and NO production in parallel with reduced superoxide anion production and NF-κB p65 expression in obese rats. Conclusions: HO-1 induction with CoPP directly improved endothelial function in obese rats independent of adiponectin changes. The mechanism of this protective effect is related to increasing NO production by activation of the AMPK-PI3K/Akt-eNOS signaling pathway.

项与 Stannous protoporphyrin 相关的新闻（医药）

2025-06-10

·PRNewswire

Renibus Therapeutics Announces FDA Orphan Drug Designation for Veverimer for the Treatment of Anti-glomerular Basement Membrane Disease (anti-GBM)

SOUTHLAKE, Texas, June 10, 2025 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to veverimer for the treatment of anti-glomerular basement membrane disease (anti-GBM), an ultra-rare life-threatening condition characterized by acute renal failure associated with the presence of auto-immune antibodies with affinity for the glomerular basement membrane. "Ultra-rare life-threatening conditions, including anti-GBM and several other forms of glomerular and tubulointerstitial kidney diseases, can be aggressive and challenging to treat effectively with current therapies," said Bhupinder Singh M.D., Chief Medical Officer of Renibus. "This Orphan Drug Designation further underscores the potential of veverimer to offer a significant advantage beyond drugs currently used to treat kidney disease, and we look forward to advancing this asset in the clinic." The Orphan Drug Designation program is intended to encourage the development of products for diseases that affect fewer than 200,000 individuals in the United States. With this designation Renibus is eligible for certain incentives, such as tax credits for clinical trials, exemption from user fees, and a potential 7 years of market exclusivity upon approval. Richard Zager, Senior Vice President of Translational Research of Renibus, commented, "Veverimer markedly suppresses ammoniagenisis and associated activation of the complement cascade, which are key mediators of anti-GBM disease and other complement mediated renal diseases. We are continuing to evaluate the potential of veverimer to address these diseases of high unmet medical need." About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' lead first-in class combination drug therapy is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. RBT-1 has just completed enrollment in a Phase 3 pivotal trial (called PROTECT) measuring its primary objective to reduce the risk of post operative complications and improve outcomes following cardiac surgery. The drug has been granted FDA Breakthrough and Fast Track Designations by the Division of Cardiology and Nephrology at the FDA. Veverimer is an oral, non-absorbed hydrochloric acid binder that has been granted Orphan Drug Designation for the treatment of anti-glomerular basement membrane disease. Renibus is also evaluating veverimer's potential use for the treatment of other renal diseases. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

孤儿药快速通道临床3期

2025-04-25

·PRNewswire

Renibus Therapeutics Announces Poster Presentation on RBT-1 at the 47th Annual Meeting of the Society of Cardiovascular Anesthesiologists (SCA)

- Renibus recently completed enrollment in a Phase 3 pivotal trial PROTECT to reduce the risk of post-operative complications and improve outcomes following cardiac surgery - SOUTHLAKE, Texas, April 25, 2025 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and metabolic diseases, today announced that a poster presentation will be delivered on RBT-1 at the 47th Annual Meeting of the Society of Cardiovascular Anesthesiologists (SCA), taking place April 26-29, 2025 in Montreal. RBT-1 is a single-dose, first-in-class, preconditioning agent that is administered intravenously 24-48 hours prior to patients undergoing non-emergent cardiac and/or valve surgery. Renibus previously completed a Phase 2 study of RBT-1 (NCT04564833) in February 2023, announced positive final results from this study in May 2023, and has recently completed enrollment in its Phase 3 PROTECT study. RBT-1 has received Breakthrough and Fast Track Designations from the US FDA. "We are excited to build on our recent momentum of achieving full enrollment in our Phase 3 PROTECT study with a poster presentation at SCA 2025 that we can share with the global anesthesiologist community," stated Jeffrey Keyser, RPh, JD, PhD, President and CEO of Renibus. "Our poster highlights the complicated economic impact of post-operative complications and increasing costs for CABG and value surgery to the healthcare system, which directly affects anesthesiologists. With the use of RBT-1 in our Phase 2 study, we reduced the complication rates from cardiovascular surgery, and in turn, the overall healthcare costs. We look forward to continuing to demonstrate these encouraging results in Phase 3." Frans van Wagenberg, MD, Huntsville Heart Center, Huntsville, Alabama, commented, "I am pleased to present results of a cost-analysis based on a Phase 2 trial which suggest that RBT-1 has a protective effect, leading to lower complication rates and reduced average expected costs overall. Additional data from an ongoing Phase 3 trial, which includes a 1-year post-discharge follow-up, will further evaluate the impact of RBT-1 on clinical, economic, and qualitative outcomes compared to standard care." Details of the poster presentation at SCA 2025: Title: "Clinical and Economic Impact of RBT-1 on Post-operative Complications and Costs for CABG and Valve Surgery" Date and Time: Sunday, April 27, 2025 at 12:30 Authors: Frans van Wagenberg, MD, Lynn Cherry, PhD, Bhupinder Singh, MD, Stacey Ruiz, PhDc, Raf Magar MB About RBT-1 RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory andantioxidant pathways currently being evaluated in the Phase 3 PROTECT study for its lead indication to reduce post-operative complications following cardiothoracic surgery. Previously, Renibus completed the Phase 2 study of RBT-1 (NCT04564833) in February 2023 and announced positive final results from this study in May 2023. In October 2023, Renibus initiated enrollment and administration of RBT-1 in its PROTECT Phase 3 pivotal study and announced completion of enrollment in April 2025. RBT-1 was granted Breakthrough Therapy designation status from the U.S. FDA to reduce the risk of complications in patients undergoing cardiothoracic surgery. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial (called PROTECT) to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations. Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. The drug has received FDA Orphan Drug Designation. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in clinical trials. Renibus has three additional assets at earlier stages of development. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期快速通道临床2期孤儿药突破性疗法

2025-03-26

·PRNewswire

Renibus to Participate in the 24th Annual Needham Healthcare Virtual Healthcare Conference

SOUTHLAKE, Texas, March 26, 2025 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and metabolic diseases, today announced its participation in the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025. This event is being held in a virtual format during which Company management will participate in one-on-one meetings with investors. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations. Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in clinical trials. Renibus has three additional assets at earlier stages of development. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期快速通道

100 项与 Stannous protoporphyrin 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床2期	美国	Renibus Therapeutics, Inc.	2020-08-05
慢性肾病	临床1期	美国	Renibus Therapeutics, Inc.	2019-03-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04072861 (CTgov)	临床1期	慢性肾病	42	RBT-9 (9 mg)	衊構鹽製膚鏇鹹餘鹽膚(鬱鏇鹹餘願獵衊築廠憲) = 積蓋淵積鑰顧艱積艱鑰構鏇顧衊餘窪繭夢簾襯 (鏇齋鬱憲衊網遞衊網遞, 壓餘鏇築觸鑰憲衊積遞 ~ 襯積餘選夢繭醖範夢憲) 更多	-	2025-01-06
				RBT-9 (27 mg)	衊構鹽製膚鏇鹹餘鹽膚(鬱鏇鹹餘願獵衊築廠憲) = 製淵夢顧淵鑰襯積範繭構鏇顧衊餘窪繭夢簾襯 (鏇齋鬱憲衊網遞衊網遞, 壓願憲遞壓願網鑰簾廠 ~ 蓋範糧憲餘簾鹽蓋鏇齋) 更多
NCT04364763 (CTgov)	临床2期	新型冠状病毒感染	42	RBT-9 (90 mg) (RBT-9 (90 mg))	簾觸衊鑰獵築鏇積觸壓(襯鬱積製艱艱壓選築鏇) = 網願蓋簾範願築遞獵積範壓壓鹹遞蓋製壓餘夢 (觸艱艱鬱鏇膚蓋選壓壓, 糧蓋鹹艱艱糧積齋範鏇 ~ 夢襯鑰糧繭願艱醖窪艱) 更多	-	2023-03-29
				0.9% sodium chloride (normal saline) (Placebo)	簾觸衊鑰獵築鏇積觸壓(襯鬱積製艱艱壓選築鏇) = 憲窪壓餘鬱鏇鑰簾夢蓋範壓壓鹹遞蓋製壓餘夢 (觸艱艱鬱鏇膚蓋選壓壓, 齋繭築蓋壓窪網淵獵製 ~ 廠願鑰鹹鹹築壓顧鹽壓) 更多